Jefferies Highlights H2 2026 Pivotal Readouts in AtaiBeckley Pipeline
Jefferies indicated that AtaiBeckley’s clinical pipeline has advanced toward several late-stage data catalysts, with pivotal trial readouts slated for the second half of 2026. The broker highlighted progression across multiple psychedelic therapy candidates, potentially unlocking near-term valuation inflection points for the venture.
1. Jefferies Marks Late-Stage Progress
Jefferies highlighted that AtaiBeckley’s joint pipeline has moved several lead candidates into late-stage clinical development, with pivotal data readouts expected in the second half of 2026. The update underscores progress across its psychedelic therapy programs and suggests potential upcoming valuation inflection points tied to these trial outcomes.
Related News
AVGO
Nvidia Predicts $91B Q3 Sales, Boosts Dividend and $80B Buyback; Broadcom Poised for AI Inference Growth
AVGO•
HOOD
Robinhood Secures $3B Wells Fargo TradePMR Team, CFO to Present May 27
HOOD•
LCLN
Lincoln International Debuts 12.6% Up, Valued at $2.3 Billion After $421M IPO
LCLN•
GOOGL
Alphabet Executes Record Yen Bond Sale as Google Secures 9.7 GWh AI Storage Contracts
GOOGL•
TGT
Target CEO Highlights Under-$10 Toy Sales Surge Despite High Costs
TGT•
Sources
F